CA2678088A1 - Combination therapy using tnf and alfa-galactosyl ceramide - Google Patents

Combination therapy using tnf and alfa-galactosyl ceramide Download PDF

Info

Publication number
CA2678088A1
CA2678088A1 CA002678088A CA2678088A CA2678088A1 CA 2678088 A1 CA2678088 A1 CA 2678088A1 CA 002678088 A CA002678088 A CA 002678088A CA 2678088 A CA2678088 A CA 2678088A CA 2678088 A1 CA2678088 A1 CA 2678088A1
Authority
CA
Canada
Prior art keywords
tnf
alfa
galcer
treatment
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002678088A
Other languages
English (en)
French (fr)
Inventor
Peter Brouckaert
Dirk Elewaut
Leander Huyghe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ghent University
Vlaams Instituut voor Biotechnologie
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2678088A1 publication Critical patent/CA2678088A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002678088A 2007-02-21 2008-02-20 Combination therapy using tnf and alfa-galactosyl ceramide Abandoned CA2678088A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07102787 2007-02-21
EP07102787.4 2007-02-21
PCT/EP2008/052055 WO2008101951A1 (en) 2007-02-21 2008-02-20 Combination therapy using tnf and alfa-galactosyl ceramide

Publications (1)

Publication Number Publication Date
CA2678088A1 true CA2678088A1 (en) 2008-08-28

Family

ID=39495301

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002678088A Abandoned CA2678088A1 (en) 2007-02-21 2008-02-20 Combination therapy using tnf and alfa-galactosyl ceramide

Country Status (6)

Country Link
US (1) US7959907B2 (enExample)
EP (1) EP2117583B1 (enExample)
JP (1) JP2010519274A (enExample)
AU (1) AU2008219269B2 (enExample)
CA (1) CA2678088A1 (enExample)
WO (1) WO2008101951A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959907B2 (en) 2007-02-21 2011-06-14 Vib Vzw Method of treating cancer by combination therapy using TNF and alpha-galactosylceramide
WO2016065353A1 (en) * 2014-10-24 2016-04-28 University Of Miami Combination therapy with fenofibrate and 2-deoxyglucose or 2-deoxymannose

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPH0559081A (ja) 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
US6001619A (en) 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
CA2376675A1 (en) 1999-06-11 2000-12-21 The Research Foundation Of State University Of New York Antagonists of bmp and tgf.beta. signalling pathways
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2005003167A1 (en) 2003-07-01 2005-01-13 Vib Vzw Ubiquitinated tnf receptor 2 and its uses
AU2005280163B2 (en) 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
US7959907B2 (en) 2007-02-21 2011-06-14 Vib Vzw Method of treating cancer by combination therapy using TNF and alpha-galactosylceramide

Also Published As

Publication number Publication date
US20100166697A1 (en) 2010-07-01
JP2010519274A (ja) 2010-06-03
US7959907B2 (en) 2011-06-14
EP2117583A1 (en) 2009-11-18
WO2008101951A1 (en) 2008-08-28
EP2117583B1 (en) 2013-05-22
AU2008219269A1 (en) 2008-08-28
AU2008219269B2 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
US4863727A (en) Combination therapy using interleukin-2 and tumor necrosis factor
JP2016132669A (ja) 関節を治療するための組成物及び方法
Nakata et al. Augmented antitumor effect of recombinant human interleukin-1α by indomethacin
AU2008219269B2 (en) Combination therapy using TNF and alfa-galactosyl ceramide
Agarwala et al. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment
Negrier et al. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer
AU2012340446B2 (en) Apoaequorin for reducing neuronal injury due to ischemia
EP0248516B1 (en) Compositions and the use of interleukin-2 and/or interferon-beta and tumour necrosis factor for combination therapy or in providing medicaments or formulations
Santini et al. Differentiation therapy of myelodysplastic syndromes: fact or fiction?
Takahashi et al. Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice
Ohno Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia
CN105358159A (zh) 用于细胞动员中的硫酸葡聚糖
Balemans et al. PEG‐IL‐2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclopphosphamide
CN101068564A (zh) 含有vegf抑制剂与5fu或其中一种衍生物的抗肿瘤组合物
Kuzmits et al. Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma
Golab et al. Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo.
Frankfurt et al. Growth factors in leukemia
ES3009748T3 (en) Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
Gottlieb Cytokine manipulation of the immune response in the treatment of human acute leukaemia
IJzermans et al. Injection of recombinant tumor necrosis factor directly into liver metastases: an experimental and clinical approach
Lasek et al. Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice
KR20210039414A (ko) 암의 치료를 위한 병용 요법
Krosnick et al. Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice
Ravandi et al. CYTOKINES IN THE TREATMENT OF ACUTE

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140220